BNGI.US Compass Biotechnologies Inc
- Market cap
- USD 14.3K
- P/E
- -
- P/B
- 6.47x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Apr 2019.
Is BNGI.US undervalued?
Graham numberThe Graham number of Compass Biotechnologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Compass Biotechnologies Inc fundamental analysis
No fundamental analysis for Compass Biotechnologies Inc yet.
Compass Biotechnologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Compass Biotechnologies Inc
Bangi Inc. acquires and leases various specialized real estate assets to the cannabis industry. Its assets include hemp and cannabis farms, dispensaries, and commercial and industrial real estate properties. The company is based in Grosse Pointe Farms, Michigan. Bangi Inc. is a subsidiary of Bangi Investments, LLC.
Full company profileCompass Biotechnologies Inc financial statements
2019 annualized: Fiscal year 2019 is not finished. Income statement and cash flow are annualized from 1 quarter up to Apr 30, 2019, the balance sheet is the latest quarter. Figures change when the annual report is published.
Compass Biotechnologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2018 | 2019 | 2019 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 28.3K | 773K | 1.36M | - | - | - | - | - | - | - | - |
| Gross Profit | 18.1K | 438K | 761K | - | - | - | - | - | - | - | - |
| Operating Income | 3.81K | 11.1K | 2.68K | -856K | -631K | -310K | -1.42M | -907K | -20.0K | -6.00K | -3.00K |
| EBITDA | 3.93K | 12.2K | 3.93K | -856K | -631K | -244K | -1.41M | - | - | - | - |
| Net Income | 1.96K | 5.07K | 1.37K | -919K | -631K | -115K | -1.63M | -876K | -433K | -324K | -3.00K |
| EPS | 0.13 | 0.00 | 0.00 | -0.93 | -0.64 | -0.05 | -0.15 | - | - | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 28.4K | 204K | 378K | 468K | 50.8K | 870K | 1.01M | 614K | 112K | 112K | 712K |
| Total Liabilities | 26.5K | 136K | 313K | 36.7K | 86.4K | 125K | 699K | 631K | 1.58M | 1.86M | 1.86M |
| Shareholders' Equity | 1.91K | 68.0K | 64.8K | 431K | -35.5K | 746K | 307K | -16.8K | -1.46M | -1.75M | -1.15M |
| Cash & Short-term Investments | 17.4K | 65.4K | 149K | 438K | 26.0K | 4.92K | 40.1K | 3.36K | - | - | - |
| Total Debt | - | - | - | - | - | 10.0K | 13.5K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.9K | -2.31K | 79.5K | -880K | -383K | -189K | -340K | -558K | -89.4K | -6.45K | -2.41M |
| Capital Expenditure | 2.45K | 1.91K | 0.00 | 2.01K | 997.00 | 98.3K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 17.5K | -4.22K | 79.5K | -882K | -383K | -287K | -340K | - | - | - | - |
| Ratios | |||||||||||
| ROE | 102.4% | 7.5% | 2.1% | -213.1% | - | -15.4% | -531.7% | - | - | - | - |
| ROA | 6.9% | 2.5% | 0.4% | -196.4% | -1,241.5% | -13.2% | -162.1% | -142.7% | -387.7% | -290.0% | -0.4% |
| Net Profit Margin | 6.9% | 0.7% | 0.1% | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | 0.01x | 0.04x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Compass Biotechnologies Inc dividends
Compass Biotechnologies Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Feb 2, 2009.
Who owns Compass Biotechnologies Inc
Ownership data of Compass Biotechnologies Inc is not available yet.
Compass Biotechnologies Inc company profile
- Company name
- Compass Biotechnologies Inc
- Ticker
- BNGI.US
- Exchange
- USA Stocks
- Sector
- Real Estate
- Industry
- Real Estate Services
- Employees
- 4
- Fiscal year end
- January
- Address
- 18530 Mack Avenue, Grosse Pointe Farms, MI, United States, 48236
- Phone
- 833-251-7679
- Website
- bangistock.com
About Compass Biotechnologies Inc
Bangi Inc. acquires and leases various specialized real estate assets to the cannabis industry. Its assets include hemp and cannabis farms, dispensaries, and commercial and industrial real estate properties. The company is based in Grosse Pointe Farms, Michigan. Bangi Inc. is a subsidiary of Bangi Investments, LLC.
Compass Biotechnologies Inc management
2- Nicole BirchChairperson, CEO & Interim Corporate Secretary
- Mr. Mathew KnowlesChief Marketing Officer & Director